Adam Lauko1, Bicky Thapa2, Vyshak Alva Venur3, Manmeet S Ahluwalia4. 1. Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA. 2. Fairview Hospital-Cleveland Clinic, Cleveland, OH, USA. 3. University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 4. Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA. ahluwam@ccf.org.
Abstract
PURPOSE OF THE REVIEW: Brain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases. RECENT FINDINGS: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer among others. They modulate the immune system to recognize tumor antigens as "non-self" antigens and mount an immune response against them. Initial studies of using immune checkpoint inhibitors in brain metastases have shown promising activity, and several clinical trials are currently underway. Studies are also assessing the combination of radiation therapy and immunotherapy in brain metastases. The results of these ongoing clinical trials have the potential to change the therapeutic paradigm in patients with brain metastases.
PURPOSE OF THE REVIEW: Brain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases. RECENT FINDINGS: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer among others. They modulate the immune system to recognize tumor antigens as "non-self" antigens and mount an immune response against them. Initial studies of using immune checkpoint inhibitors in brain metastases have shown promising activity, and several clinical trials are currently underway. Studies are also assessing the combination of radiation therapy and immunotherapy in brain metastases. The results of these ongoing clinical trials have the potential to change the therapeutic paradigm in patients with brain metastases.
Authors: Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf Journal: Lancet Oncol Date: 2012-10-08 Impact factor: 41.316
Authors: Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Sagun Parakh; John J Park; Shehara Mendis; Rajat Rai; Wen Xu; Serigne Lo; Martin Drummond; Catherine Rowe; Annie Wong; Grant McArthur; Andrew Haydon; Miles C Andrews; Jonathan Cebon; Alex Guminski; Richard F Kefford; Georgina V Long; Alexander M Menzies; Oliver Klein; Matteo S Carlino Journal: Br J Cancer Date: 2017-05-18 Impact factor: 7.640
Authors: Y S Yap; G H Cornelio; B C R Devi; C Khorprasert; S B Kim; T Y Kim; S C Lee; Y H Park; J H Sohn; N Sutandyo; D W Y Wong; M Kobayashi; S H Landis; E M Yeoh; H Moon; J Ro Journal: Br J Cancer Date: 2012-08-23 Impact factor: 7.640
Authors: Bridget A Kennis; Keith A Michel; William B Brugmann; Alvaro Laureano; Rong-Hua Tao; Srinivas S Somanchi; Samuel A Einstein; Javiera B Bravo-Alegria; Shinji Maegawa; Andrew Wahba; Simin Kiany; Nancy Gordon; Lucia Silla; Dawid Schellingerhout; Soumen Khatua; Wafik Zaky; David Sandberg; Laurence Cooper; Dean A Lee; James A Bankson; Vidya Gopalakrishnan Journal: J Neurooncol Date: 2019-02-20 Impact factor: 4.130
Authors: Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram Journal: Theranostics Date: 2019-07-09 Impact factor: 11.556
Authors: Eduardo E Lovo; Leonel B Torres; Fidel J Campos; Victor E Caceros; Kaory E Barahona; Mario H Minervini; William A Reyes Journal: Cureus Date: 2019-08-24
Authors: Richard S P Huang; James Haberberger; Kimberly McGregor; Douglas A Mata; Brennan Decker; Matthew C Hiemenz; Mirna Lechpammer; Natalie Danziger; Kelsie Schiavone; James Creeden; Ryon P Graf; Roy Strowd; Glenn J Lesser; Evangelia D Razis; Rupert Bartsch; Athina Giannoudis; Talvinder Bhogal; Nancy U Lin; Lajos Pusztai; Jeffrey S Ross; Carlo Palmieri; Shakti H Ramkissoon Journal: Oncologist Date: 2021-06-23